today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be ...

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops ...

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical ...

Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment. Candel Therapeutics, Inc. announced the acceptance of an ...

The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global ...

The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global ...

The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media.

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival ...

announced that the Phase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma will be ...

Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s ...